½ÃÀ庸°í¼­
»óǰÄÚµå
1405759

Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ® ÃæÀüÀç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Calcium Hydroxylapatite Fillers Market Size, Share & Trends Analysis Report By Application (Facial Wrinkles And Folds, Jawline Contouring, Lipoatrophy), By End Use (MedSpas, Cosmetic Surgery Center, Hospitals), And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ® ÃæÀüÀç ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç ½ÃÀåÀº 2030³â±îÁö 16¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2030³âÀÇ CAGRÀº 13.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀº ´õ¸» ÇÊ·¯ Á¶ÇÕ¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ È®´ë, ¼±Áø±¹ ¹× ½ÅÈï ±¹°¡ÀÇ ¹Ì¿ë ±âÁØ º¯È­, ȯÀÚ¿¡°Ô À¯¸®ÇÑ °æÁ¦Àû Á¢±Ù ¿É¼Ç, ¾ó±¼ ÁÖ¸§°ú ºÎÇÇ °¨¼Ò¿¡ Ãë¾àÇÑ ³ëÀΠȯÀÚ Àα¸ Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

÷´Ü Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÇÊ·¯ÀÇ Ã¤Åðú °³¹ßÀÌ Áõ°¡Çϸ鼭 ÀÌ »ê¾÷ÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. È÷¾Ë·ç·Ð»ê(HA)°ú Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA)¸¦ ÅëÇÕÇÏ¿© ¾ó±¼ ºÎÇÇ °¨¼Ò·Î °í¹ÎÇϴ ȯÀÚµéÀ» µ½´Â °ÍÀÌ ¼ºÀå¿¡ µµ¿òÀÌ µË´Ï´Ù. ¿¹¸¦ µé¾î HA´Â Áï°¢ÀûÀÎ º¼·ý Áõ°¡ È¿°ú¿¡ ±â¿©Çϰí ÀÜÁÖ¸§°ú ÀÜÁÖ¸§À» ÇØ°áÇÕ´Ï´Ù. ¶ÇÇÑ CaHAÀÇ Äݶó°Õ ÀÚ±Ø Æ¯¼ºÀº Áö¼ÓÀûÀÎ È¿°ú¸¦ °¡Á®¿Í Ä¡·áÀÇ ¼ö¸íÀ» ¿¬ÀåÇÕ´Ï´Ù.

Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀçÀÇ ÁÖ¿ä ¾÷üµéÀÇ Àü·«Àû ±¸»óÀÌ Áõ°¡Çϸ鼭 ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 9¿ù CGBio´Â Àεµ³×½Ã¾Æ¿¡¼­ ÇÊ·¯ Á¦Ç°±º FACETEMÀ» Ãâ½ÃÇß½À´Ï´Ù. ±× °á°ú, 2023³â 10¿ù CGBio´Â Áß±¹ º»Åä¿¡¼­ CaHA ÇÊ·¯ °ø±ÞÀ» È®´ëÇϱâ À§ÇØ HTDK¿Í 1¾ï ´Þ·¯ ±Ô¸ðÀÇ ¼öÃâ °è¾àÀ» ü°áÇß½À´Ï´Ù. ¶ÇÇÑ 2020³â 10¿ù¿¡´Â ´õ¸» ÇÊ·¯ Æ÷Æ®Æú¸®¿À¿Í ÆÄÀÌÇÁ¶óÀÎÀ» º¸À¯ÇÑ À̽º¶ó¿¤ÀÇ ·ç¹Ì³×¶ó(Luminera)¸¦ ÀμöÇß½À´Ï´Ù.

Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ® ÃæÀüÀç ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ÇコÄÉ¾î ½ÃÀåÀÇ Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç »ê¾÷Àº 2023³â 6¾ï4810¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2030³â¿¡´Â 16¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÀÌ ½ÃÀåÀº 2024-2030³â ¿¬Æò±Õ 13.8%ÀÇ º¹ÇÕ ¼ºÀå·ü·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 16¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • 2023³â¿¡´Â ºÏ¹Ì°¡ 35.2%ÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹¿¡¼­´Â ÇǺΠ°áÇÔ°ú Áúº´¿¡ Ãë¾àÇÑ ³ë·É Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇÊ·¯ ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¿ëµµº°·Î´Â ¾ó±¼ ÁÖ¸§ ¹× ÁÖ¸§ ºÐ¾ß°¡ 2023³â 51.24%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â CaHA ÇÊ·¯°¡ ÁÖ¸§À» È¿°úÀûÀ¸·Î ¾ø¾Ö°í ³ëÈ­·Î ÀÎÇÑ ÇÇºÎ ÆØÃ¢ ¼Õ½ÇÀÇ ¿µÇâÀ»¹Þ´Â ºÎÀ§¿¡ º¼·ýÀ» Ãß°¡ ÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â 2023³â ÀÇ·á¿ë ½ºÆÄ ºÎ¹®ÀÌ 51.56%·Î ¾ÐµµÀûÀÎ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì¿ë ÇÊ·¯ ½Ã¼úÀº ȯÀÚÀÇ ´Ù¿îŸÀÓÀÌ Âª°í ¹Ì¿ë ¼ö¼úÀÇ ºñħ½ÀÀû Ư¼ºÀ¸·Î ÀÎÇØ ÁÖ·Î ÀÇ·á±â°ü¿¡¼­ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¤ÀÇ¿Í ¹üÀ§
    • ¾ó±¼ ÁÖ¸§¡¤ÁÖ¸§
    • Åμ± ÄÁÅõ¾î¸µ
    • Áö¹æÀ§ÃàÁõ
    • ±âŸ
  • ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ¿ëµµº° ¼¼°èÀÇ Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç ½ÃÀå Àü¸Á
  • ÀÌÇÏ ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
    • ¾ó±¼ ÁÖ¸§¡¤ÁÖ¸§
    • Åμ± ÄÁÅõ¾î¸µ
    • Áö¹æÀ§ÃàÁõ
    • ±âŸ

Á¦5Àå Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¤ÀÇ¿Í ¹üÀ§
    • MedSpas
    • ¹Ì¿ë¼ºÇü ¼¾ÅÍ
    • º´¿ø
  • ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ÃÖÁ¾ ¿ëµµº° ¼¼°èÀÇ Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç ½ÃÀå Àü¸Á
  • ÀÌÇÏ ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
    • MedSpas
    • ¹Ì¿ë¼ºÇü ¼¾ÅÍ
    • º´¿ø

Á¦6Àå Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®(CaHA) ÃæÀüÀç ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°èÀÇ Áö¿ª ½ÃÀå ½º³À¼ô
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â :
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ȸ»ç/°æÀïÀÇ ºÐ·ù
    • À̳뺣ÀÌÅÍ
  • º¥´õ ±¸µµ
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Merz Pharma
    • AbbVie Inc.
    • CGBio
    • Cytophil, Inc.
    • DR. Korman.
    • Luminera
KSA 24.01.22

Calcium Hydroxylapatite Fillers Market Growth & Trends:

The global calcium hydroxylapatite (CaHA) fillers market is expected to reach USD 1.6 billion by 2030 and it is projected to grow at a CAGR of 13.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to grow due to factors such as growing regulatory approvals for combination dermal fillers, changing aesthetic standards across developed and developing countries, favorable financial accessibility options for patients, and an increasing population of geriatric patients susceptible to facial wrinkles and volume loss.

The industry's growth is driven by the increasing adoption and development of advanced calcium hydroxylapatite (CaHA) fillers. The integration of hyaluronic acid (HA) with calcium hydroxylapatite (CaHA) to aid in patients suffering from facial volume loss aids growth. For instance, HA contributes to immediate volumizing effects, addressing fine lines and wrinkles. In addition, CaHA's collagen-stimulating properties lead to sustaining results, extending the longevity of the treatment.

An increase in strategic initiatives amongst the key players of calcium hydroxylapatite (CaHA) fillers is anticipated to propel growth. For instance, in September 2023, CGBio launched its filler range, FACETEM, in Indonesia. Consequently, in October 2023, CGBio signed an export contract worth 100 million USD with HTDK to expand its CaHA filler offerings in Mainland China. Furthermore, in October 2020, AbbVie Inc. acquired Luminera, a company based in Israel with a portfolio and pipeline of dermal fillers.

Calcium Hydroxylapatite Fillers Market Report Highlights:

  • The calcium hydroxylapatite (CaHA) fillers industryin the healthcare market was estimated at USD 648.1 Million in 2023 and is expected to reach USD 1.6 Billion in 2030
  • The marketis expected to grow at a compound annual growth rate of 13.8% from 2024 to 2030 to reach USD 1.6 Billion by 2030
  • In 2023, North America held the largest share of the market, with a revenue share of 35.2%. The growing geriatric population in the U.S., which is susceptible to skin imperfections or diseases, is expected to increase the demand for filler procedures, thereby significantly contributing to the market growth over the forecast period
  • By application, the facial wrinkles and folds segment accounted for the largest revenue share of 51.24% in 2023 driven by the ability of CaHA filler to effectively diminish lines and add volume in areas affected by age-related loss of skin fullness
  • By end use, the medspas segment accounted for a dominant revenue share of 51.56% in 2023. Aesthetic filler procedures are primarily performed by medspas owing to low patient downtime and the non-invasive nature of cosmetic surgery

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Application
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Calcium Hydroxylapatite (CaHA) Fillers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing preference for non-aesthetic cosmetic procedures
      • 3.2.1.2. Technological advancements in facial injectables
      • 3.2.1.3. Growing geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Presence of alternative treatment options
      • 3.2.2.2. High procedure cost and growing control by regulatory bodies
  • 3.3. Calcium Hydroxylapatite (CaHA) Fillers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Calcium Hydroxylapatite (CaHA) Fillers Market: Application Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Facial wrinkles and folds
    • 4.1.2. Jawline contouring
    • 4.1.3. Lipoatrophy
    • 4.1.4. Others
  • 4.2. Application Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Calcium Hydroxylapatite (CaHA) Fillers Market by Application Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Facial wrinkles and folds
      • 4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Jawline contouring
      • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.3. Lipoatrophy
      • 4.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Calcium Hydroxylapatite (CaHA) Fillers Market: End-Use Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. MedSpas
    • 5.1.2. Cosmetic surgery centers
    • 5.1.3. Hospitals
  • 5.2. End-Use Market Share, 2023 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Global Calcium Hydroxylapatite (CaHA) Fillers Market by End-Use Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. Medspas
      • 5.5.1.1. Market estimates and forecast 2018 to 2030 (USD million)
    • 5.5.2. Cosmetic surgery centers
      • 5.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.3. Hospitals
      • 5.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Calcium Hydroxylapatite (CaHA) Fillers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Norway market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Innovators
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Merz Pharma
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. AbbVie Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. CGBio
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Cytophil, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. DR. Korman.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Luminera
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦